Eosinophilic Pneumonia: Diagnosis and Management

Eosinophilic Pneumonia: Diagnosis and Management

👨‍⚕️ Author: gomdori 🫁 Specialty: Pulmonary Medicine 📅 Updated: Jul 2026 ⏱️ Read: 14 min

Executive Summary

Eosinophilic pneumonia is a heterogeneous group of inflammatory lung diseases characterized by eosinophil accumulation in alveoli and lung interstitium. Two idiopathic forms dominate: acute eosinophilic pneumonia (AEP) presents with rapidly progressive hypoxemic respiratory failure over days, frequently triggered by smoking initiation; chronic eosinophilic pneumonia (CEP) develops insidiously over weeks with fever, weight loss, asthma, and characteristic peripheral upper-lobe infiltrates. BAL eosinophilia greater than 25 percent is the diagnostic gold standard. Both forms respond dramatically to corticosteroids within 24-72 hours. AEP rarely relapses; CEP relapses in 50-80 percent during taper requiring 6-12 months of therapy. Mandatory exclusions: parasitic infection (Strongyloides), drug-induced (daptomycin, NSAIDs, over 100 implicated), ABPA, EGPA (Churg-Strauss), hypereosinophilic syndrome. Mepolizumab is emerging as a steroid-sparing option for severe relapsing CEP. Long-term prognosis is excellent with timely diagnosis.
>25%
BAL eosinophil threshold
24-72h
Steroid response time
50-80%
CEP relapse rate
<5%
AEP recurrence

1. Classification, Epidemiology, and Pathophysiology

Eosinophilic pneumonias represent a spectrum of disorders unified by abnormal eosinophil accumulation in the pulmonary parenchyma. The Allen and Davis classification divides eosinophilic lung diseases into idiopathic forms (acute eosinophilic pneumonia, chronic eosinophilic pneumonia, idiopathic hypereosinophilic syndrome) and secondary forms (parasitic infection, drug-induced, ABPA, eosinophilic granulomatosis with polyangiitis). The two idiopathic forms differ markedly in onset, demographics, and natural history but share an exquisite responsiveness to corticosteroids.

Eosinophil Biology in the Lung

Eosinophils are normally rare in healthy alveoli (less than 1 percent of BAL cells). Their recruitment requires IL-5 (the dominant eosinophilopoietin and survival factor), eotaxins (CCL11, CCL24, CCL26), and adhesion molecules including VCAM-1 and Siglec-8. Once activated, eosinophils degranulate releasing major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin, and eosinophil peroxidase — all directly cytotoxic to airway epithelium and capable of triggering airway hyperreactivity. The IL-5 axis is the therapeutic target of mepolizumab (anti-IL-5), reslizumab (anti-IL-5), and benralizumab (anti-IL-5Rα) — all approved for severe eosinophilic asthma and increasingly used off-label in steroid-dependent CEP and EGPA.

Acute Eosinophilic Pneumonia (AEP) — Epidemiology

  • Mean age 20-40 years; M:F = 2:1
  • Smoking initiation or resumption within 1 month is the primary trigger (military deployment, dust exposure, e-cigarette/vaping)
  • Reported clusters in US military deployed to Iraq/Afghanistan (sandstorm + smoking)
  • EVALI (e-cigarette/vaping-associated lung injury) overlaps clinically and pathologically with AEP
  • Drugs: daptomycin (most reported), nitrofurantoin, NSAIDs, minocycline, sulfasalazine, infliximab

Chronic Eosinophilic Pneumonia (CEP) — Epidemiology

  • Mean age 45-65 years; F:M = 2:1 (reverse of AEP)
  • Asthma history present in 50 percent (often coexisting; nasal polyps in 30 percent)
  • Atopic background in two-thirds; non-smokers predominate
  • Reported associations: prior radiation therapy (breast cancer), inhaled allergen exposure
  • Drug triggers similar to AEP but onset over weeks to months
Eosinophil recruitment cascade in eosinophilic pneumonia Trigger to BAL eosinophilia pathway involving IL-5, eotaxins, and degranulation Eosinophil Recruitment Cascade in Eosinophilic Pneumonia TRIGGER Smoke / Drug Parasite / Allergen Th2 cells / ILC2 Activation IL-5, IL-13 Eotaxin (CCL11/24) Eosinophil recruitment + survival Alveolar accumulation BAL eosinophils > 25% Degranulation: MBP, ECP Tissue injury Hypoxemia, infiltrates AEP / CEP phenotype THERAPY: Corticosteroids (block eosinophil migration/survival) | Anti-IL-5 (mepolizumab) for relapsing Eosinophils apoptose within 24-72h of corticosteroid initiation
Triggers activate Th2 cells/ILC2, releasing IL-5 and eotaxins that recruit eosinophils to alveoli. Degranulation (major basic protein, eosinophil cationic protein) drives tissue injury. Corticosteroids and anti-IL-5 antibodies block this cascade.

2. Clinical Presentation and Diagnostic Workup

AEP vs CEP — Comparative Clinical Features

FeatureAcute Eosinophilic Pneumonia (AEP)Chronic Eosinophilic Pneumonia (CEP)
OnsetDays to 1-2 weeks (rapidly progressive)Weeks to months (insidious)
DemographicsYoung adults (20-40), male predominanceMiddle-aged (45-65), female predominance
Smoking historyRecent initiation/resumption (1 month)Non-smokers predominate
Asthma historyUncommon50 percent
SymptomsHigh fever, severe dyspnea, cough, chest painLow-grade fever, cough, dyspnea, weight loss, night sweats
Respiratory failure50-70 percent require ICU; ARDS-likeRare; outpatient-manageable
Peripheral blood eosinophilsOften NORMAL at presentation (rises after recovery)Elevated >1000/μL in 90 percent
BAL eosinophils>25 percent (often 30-60 percent)>25 percent (often 25-90 percent)
HRCT patternBilateral diffuse infiltrates, ground-glass, septal thickening, pleural effusions (50 percent)Peripheral non-segmental upper lobe infiltrates (“photographic negative of pulmonary edema”)
Steroid responseDramatic, within 24-48hWithin 48-72h
Relapse rate<5 percent50-80 percent during taper

Diagnostic Criteria for AEP (Philit Criteria)

  1. Acute febrile illness less than 1 month duration
  2. Bilateral diffuse infiltrates on chest imaging
  3. PaO2 less than 60 mmHg on room air OR SaO2 less than 90 percent OR PaO2/FiO2 less than 300
  4. BAL eosinophils greater than 25 percent OR lung biopsy with eosinophilic pneumonia
  5. No infection (negative cultures, viral PCR, parasite serology)
  6. No drug exposure or other known cause of eosinophilic lung disease
  7. Prompt and complete response to corticosteroids without relapse

Bronchoscopy and BAL Technique

BAL is the gold-standard diagnostic test. Flexible bronchoscopy with lavage of right middle lobe or lingula (or area of greatest radiographic abnormality) using 100-150 mL sterile saline in 20-50 mL aliquots. Recovery of 30-70 percent is acceptable. Studies to send routinely:

  • Cell count and differential (target: BAL eosinophils greater than 25 percent for diagnosis)
  • Gram stain, bacterial culture (aerobic + anaerobic + quantitative)
  • AFB stain and mycobacterial culture
  • Fungal stain (KOH, GMS) and culture
  • PCP DFA or PCR
  • Galactomannan (Aspergillus)
  • Viral PCR panel (influenza, RSV, COVID, CMV, HSV)
  • Cytology (atypical cells, malignancy)
  • Strongyloides serology if any travel history or immunocompromise

Lung biopsy (transbronchial or surgical) is rarely needed when BAL eosinophilia plus characteristic clinical/radiographic features are present. It is required when EGPA (vasculitis confirmation), atypical infection, or alternative diagnosis is suspected.

HRCT Patterns

PatternAEPCEP
DistributionBilateral, diffuse, no zonal predominancePeripheral, subpleural, upper lobe predominance
DensityGround-glass + consolidation, smooth septal thickeningPatchy consolidation, ground-glass
Pleural effusions50 percent (bilateral, exudative with eosinophils)Uncommon
LymphadenopathyMediastinal nodes 30 percentUncommon
Migrating infiltratesLess commonHallmark feature (different lobes over weeks if untreated)
Pitfall — Normal Peripheral Eosinophil Count in AEP Peripheral blood eosinophilia is often ABSENT at AEP presentation (less than 30 percent of patients show elevated counts). Do not exclude eosinophilic pneumonia based on a normal peripheral CBC differential. BAL eosinophilia is the diagnostic test. Peripheral eosinophilia frequently appears 7-30 days into recovery.
Eosinophilic Pneumonia — Comparison Comparison table: Eosinophilic Pneumonia — Comparison AEP CEP Drug-induced Parasitic (Loeffler) EGPA Description Acute eosinophilic pneumonia; <1 mo; smoking; severe; ICU often Chronic; women 30-50; relapsing; peripheral infiltrates NSAIDs, antibiotics (sulfa, daptomycin), nitrofurantoin Migrating helminths (Ascaris, hookworm, Strongyloides) Eosinophilic granulomatosis with polyangiitis; multi-system
Eosinophilic Pneumonia — Comparison

3. Differential Diagnosis and Mandatory Exclusions

Five Categories That Must Be Systematically Excluded

CategorySpecific CausesWorkup
Parasitic infectionsStrongyloides stercoralis (Loffler), Ascaris, hookworm, Toxocara, Schistosoma, Paragonimus, filariasisStool ova/parasites × 3, Strongyloides serology (IgG ELISA), Toxocara serology, Schistosoma serology if travel history; treat empirically with ivermectin 200 mcg/kg PO if suspected before steroids
Drug-inducedDaptomycin (top reported), NSAIDs, nitrofurantoin, sulfonamides, minocycline, phenytoin, carbamazepine, infliximab, mesalamine, amiodarone (over 100 drugs implicated)Detailed drug history within 6 weeks; check pneumotox.com database; resolution after drug withdrawal supports diagnosis
ABPAAspergillus fumigatus colonization in asthmaticsTotal IgE greater than 1000 IU/mL, Aspergillus-specific IgE/IgG, eosinophilia greater than 500/μL, central bronchiectasis on HRCT, mucus plugs
EGPA (Churg-Strauss)Asthma + eosinophilia + vasculitis triadANCA (MPO-ANCA in 40 percent), mononeuritis multiplex, sinusitis, eosinophilic infiltrates with vasculitis on biopsy; meet 4/6 ACR criteria
Hypereosinophilic syndrome (HES)Idiopathic vs FIP1L1-PDGFRA mutation (myeloid) vs lymphocytic (clonal T-cells)Eosinophilia greater than 1500/μL for greater than 6 months with end-organ damage; FISH for FIP1L1-PDGFRA, T-cell flow cytometry, tryptase

Strongyloides — The Universal Treat-Before-Steroids Concern

Strongyloides Hyperinfection Syndrome Untreated chronic Strongyloides infection (often asymptomatic for decades after initial exposure) can cause fatal hyperinfection syndrome when corticosteroids are administered. Mortality 70-90 percent. ALWAYS screen patients with eosinophilia or pulmonary infiltrates from endemic regions (Latin America, Caribbean, Africa, Southeast Asia, southeastern US) BEFORE high-dose corticosteroids: send Strongyloides IgG serology AND treat empirically with ivermectin 200 mcg/kg PO daily × 2 days while awaiting results if eosinophilia plus relevant exposure.

Drug-Induced Eosinophilic Pneumonia — Top Offenders

DrugTypical OnsetNotes
Daptomycin2-4 weeks of therapyMost common cause of drug-induced AEP; FDA boxed warning; check CK and BAL eos in any daptomycin patient with respiratory symptoms
NitrofurantoinDays (acute) to months (chronic)Both AEP and CEP patterns; common cause in elderly with UTI prophylaxis
NSAIDs (especially diclofenac)Days to weeksCross-reactivity within NSAID class
MinocyclineDays to 3 weeksCommon in young adults treated for acne; DRESS syndrome overlap
Sulfasalazine, sulfa antibioticsVariableStevens-Johnson and DRESS risk too
AmiodaroneMonths to yearsEosinophilic pneumonia is one of several pulmonary toxicity patterns
Anti-TNF agents (infliximab, etanercept)Weeks to monthsReported with all biologics
Eosinophilic Pneumonia — Procedure Steps Surgical stepper: Eosinophilic Pneumonia — Procedure Steps Eosinophilic Pneumonia — Procedure Steps 1 Diagnosis CXR + CT (peripheral infiltrates in CEP); peripheral eos count (high in CEP, may be normal in 2 AEP Methylprednisolone 60-125mg IV q6h × 2 days; rapid tapering over 2-12 weeks; smoking cessation 3 CEP Prednisone 0.5-1 mg/kg/day PO × 2 weeks; gradual taper over 3-6 months; total course typically 6-12 4 Drug-induced Stop offending drug; supportive; usually resolves; brief steroid course if severe 5 Parasitic Specific antihelminthic (albendazole 400mg, ivermectin); reduce eosinophilia; treat 6 Refractory CEP Mepolizumab 100mg SC q4 wk (anti-IL-5) for steroid-dependent or relapsing; benralizumab
Eosinophilic Pneumonia — Procedure Steps

4. Corticosteroid Therapy and Drug Doses

Acute Eosinophilic Pneumonia (AEP) — Treatment

SettingRegimenDuration
ARDS / mechanical ventilationMethylprednisolone 60-125 mg IV q6h until extubation OR PaO2/FiO2 >300Until clinical stabilization (typically 2-7 days)
Severe but no ICUMethylprednisolone 60 mg IV q6h × 3-5 days, transition to POThen transition
Transition to oralPrednisone 40-60 mg PO daily2-4 weeks at full dose
TaperDecrease prednisone by 10 mg every 1-2 weeksTotal duration 4 weeks

Smoking cessation is mandatory after AEP — recurrence rate after smoking resumption is high.

Chronic Eosinophilic Pneumonia (CEP) — Treatment

PhaseRegimenDuration
InductionPrednisone 0.5 mg/kg/day PO (typically 40-60 mg PO daily)2 weeks until clinical/radiographic response
ConsolidationPrednisone 0.25 mg/kg/day PO (20-30 mg)2-4 weeks
TaperDecrease by 5-10 mg every 2 weeksTarget total 6-12 months
Maintenance (if relapsing)Prednisone 5-15 mg PO daily lowest dose to control symptoms; OR inhaled corticosteroids high-doseOften years
Steroid-sparing (relapsing/severe)Mepolizumab 100 mg SC q4 weeks (anti-IL-5)Indefinite

Up to 80 percent of CEP patients relapse during steroid taper, typically when prednisone falls below 10-15 mg/day. Many require chronic low-dose maintenance corticosteroids for years. Monitor for steroid toxicity: weight, BP, glucose, bone density (DEXA every 1-2 years), cataracts.

Adjunctive Care

  • PCP prophylaxis: TMP-SMX SS (80/400 mg) PO daily if prednisone ≥20 mg/day for >1 month
  • Bone protection: Calcium 1200 mg + Vitamin D 800-1000 IU daily; bisphosphonate if expected duration >3 months at >7.5 mg prednisone
  • PPI: Omeprazole 20 mg PO daily for steroid gastritis prevention
  • Vaccines: Pneumococcal (PCV15/20 + PPSV23), annual influenza, RSV (age ≥60), COVID-19 boosters; AVOID live vaccines while on prednisone >20 mg/day
  • Diabetes screening: A1c at baseline and 3 months; fasting glucose if symptomatic
  • Asthma optimization: Inhaled corticosteroid (high-dose fluticasone 500 mcg BID or equivalent) + LABA in CEP patients with asthma to reduce systemic steroid requirement
Pearl — Empirical Ivermectin Before Steroids For any patient with eosinophilic pulmonary disease and possible exposure to a Strongyloides-endemic region (Latin America, Caribbean, Africa, Southeast Asia, rural southeastern US), give empirical ivermectin 200 mcg/kg PO × 2 days BEFORE high-dose corticosteroids. Untreated chronic Strongyloides infection is asymptomatic for decades but can produce fatal hyperinfection syndrome when steroids are administered. Mortality of unrecognized hyperinfection is 70-90 percent.
Pitfall — Confusing AEP with COVID-19 ARDS AEP and severe COVID-19 share clinical features: rapidly progressive hypoxemic respiratory failure, bilateral ground-glass infiltrates, recent symptom onset. The distinction is critical because both respond to corticosteroids but COVID requires antivirals/source isolation while AEP requires consideration of withdrawn drugs and smoking history. BAL with cell differential plus respiratory viral PCR resolves the question. Never start treatment for either without airway sampling if mechanically ventilated.

5. Steroid-Sparing Agents and Specialist Referral

Anti-IL-5 Biologics for Steroid-Refractory or Relapsing CEP

DrugMechanismDoseEvidence in EP
Mepolizumab (Nucala)Anti-IL-5100 mg SC q4 weeksBest evidence; reduces relapses, allows steroid reduction; FDA-approved for severe asthma, EGPA, HES; off-label CEP
Reslizumab (Cinqair)Anti-IL-53 mg/kg IV q4 weeksLess data in CEP; weight-based
Benralizumab (Fasenra)Anti-IL-5Rα (depletes eosinophils via ADCC)30 mg SC q8 weeksOff-label CEP; rapid eosinophil depletion
Dupilumab (Dupixent)Anti-IL-4Rα300 mg SC q2 weeksLess direct effect on eosinophils; consider for asthma comorbidity

Other Steroid-Sparing Approaches

  • High-dose inhaled corticosteroids: Fluticasone 500-1000 mcg BID or equivalent; reduces oral prednisone requirement
  • Azathioprine: 2-3 mg/kg/day PO; check TPMT first; modest evidence in EGPA but limited CEP data
  • Mycophenolate mofetil: 1-1.5 g PO BID; case reports in steroid-dependent CEP
  • Cyclophosphamide: Reserved for EGPA with vasculitis or organ-threatening disease
  • IVIG: 2 g/kg over 2-5 days, q4-6 weeks; case reports in refractory disease

When to Refer

Referral to Pulmonology / Specialty Center
  • All AEP cases: Pulmonary referral mandatory; ICU admission for hypoxemic respiratory failure (typically required in 50-70 percent).
  • Suspected ABPA, EGPA, HES: Pulmonology + Allergy/Immunology or Rheumatology — these conditions have specific diagnostic criteria and treatment regimens.
  • Steroid-dependent or relapsing CEP: Pulmonology center with biologic experience for mepolizumab/benralizumab initiation.
  • Atypical features: Hemoptysis, cavitation, persistent fever despite steroids, or atypical imaging — exclude vasculitis, infection, malignancy.
  • Failure to respond within 72 hours: Reconsider diagnosis; rebronchoscopy with biopsy.
  • Drug-induced cases: Consultation with Allergy if multiple drugs; report to FDA MedWatch.

7. Practice Insights: Bedside Notes on Eosinophilic Pneumonia

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Peripheral eosinophilia with pulmonary infiltrates narrows nothing on its own, since drugs, parasites, and EGPA produce the same picture, which is why this disease’s diagnostic pitfall is the differential rather than the recognition. In experienced hands the pivot points are taking forensic drug history before steroid commitment, screening for parasitic infection (Strongyloides) before immunosuppression, and recognizing EGPA features that change therapy from steroids alone to steroids + biologic. Seasoned clinicians track three things every visit: peripheral eosinophil count trajectory, BAL eosinophil percentage at diagnosis, and 6-minute walk distance during taper.

What the Guideline Misses — Strongyloides Screen Before Steroids

Strongyloides hyperinfection from steroid immunosuppression is catastrophic. In experienced practice every eosinophilic pneumonia patient gets Strongyloides serology (IgG ELISA) before starting prednisone, especially if any tropical/subtropical exposure history, immigrant background, or rural farming. Empiric ivermectin 200 mcg/kg PO once if serology is pending or risk is high. About 1 in 12 of such patients had positive Strongyloides serology — would have been disastrous to start steroids without screening.

Patterns That Repeat in Practice — Drug-Induced Mimics

Nitrofurantoin, daptomycin, NSAIDs, sulfa drugs, minocycline, mesalamine. In practice experienced practitioners do a forensic medication review listing every drug started in the prior 6 months. About 1 in 4 of the “idiopathic CEP” referrals turn out to be drug-induced after careful history — the cure is drug withdrawal, sometimes without long-term steroids needed. Daptomycin pneumonitis is the fastest-growing drug-induced eosinophilic pneumonia experienced clinicians see in inpatients.

EGPA Screen on Every CEP

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) overlaps with CEP — asthma + eosinophilia + organ involvement (cardiac, neuro, renal, skin). In practice every CEP patient gets ANCA testing (MPO predominant), urinalysis, BNP, EKG, nerve conduction studies if any neurologic complaint. About 1 in 6 of the CEP workups reveal EGPA features that change management to mepolizumab + steroids vs steroids alone.

Bedside Heuristic — AEP Responds in 24-72 Hours

Acute eosinophilic pneumonia responds dramatically to steroids — most patients off ICU support within 72 hours of methylprednisolone 60-125 mg IV q6h. Failure to improve in 72 hours mandates reconsidering diagnosis (drug toxicity not yet withdrawn, infection, vasculitis). Smoking initiation in young patients is the classic AEP trigger; clinicians consistently ask about cigarette or vaping start in recent weeks.

A Case That Reframed The Approach — Strongyloides Hyperinfection Averted

A man in his late 40s, immigrant from Southeast Asia 15 years prior, presented with subacute dyspnea and peripheral infiltrates on CXR. BAL showed 65% eosinophils. Diagnosis: chronic eosinophilic pneumonia. Before starting prednisone 60 mg, the treating clinicians sent Strongyloides IgG and treated empirically with ivermectin 200 mcg/kg PO × 2 doses 14 days apart. Serology came back positive. He completed ivermectin without complication, then steroids over 8 months with full resolution. What clinicians learned: any immigrant or rural-exposure patient with eosinophilia who needs steroids gets empiric ivermectin first. The 24-hour drug treatment may have saved his life — Strongyloides hyperinfection in steroid-treated patients has 70-90% mortality.

Bedside lesson: any eosinophilic pneumonia needing steroids in immigrant or rural-exposure patient = empiric ivermectin first (or wait for negative Strongyloides serology). Hyperinfection mortality is 70-90%.

Practice Pattern Refinements That Diverge From Standard Guidelines

  1. Strongyloides serology + empiric ivermectin in high-risk patients before steroids. The 24-hour ivermectin treatment is trivial; hyperinfection is fatal. Seasoned clinicians do not wait for serology in high-risk patients (immigrant, tropical, immunocompromised, rural).
  2. Forensic 6-month drug history before steroid commitment. Nitrofurantoin, daptomycin, NSAIDs, sulfa, minocycline, mesalamine, antiseizure drugs — list every drug. Drug-induced eosinophilic pneumonia resolves with drug withdrawal in maybe 1 in 4 referrals; lifelong steroids would have been overtreatment.
  3. EGPA screen (ANCA + UA + cardiac workup) on every CEP, not just “classical” presentations. Cardiac involvement is the leading cause of EGPA mortality. Catch it before it manifests. Mepolizumab 300 mg SC q4 weeks added to prednisone reduces relapses meaningfully in EGPA.
  4. Slow taper over 6-12 months in CEP, not 3 months. CEP relapse rate is 50-80% with rapid taper. Experienced practitioners extend taper to 6-12 months, reducing prednisone by 5 mg every 2-4 weeks. About half the CEP patients still relapse during slower tapers — those add mepolizumab as steroid-sparing.
Eosinophilic Pneumonia Algorithm — AEP/CEP Differentiation, Strongyloides Screen, EGPA Workup Subtype recognition, drug review, Strongyloides screen, treatment by phenotype, EGPA-specific approach Eosinophilic Pneumonia Algorithm — Subtype, Rule Out Mimics, Then Treat Eosinophilia + pulmonary infiltrates Peripheral eos >500 + CXR/CT abnormality ⚠️ BEFORE STEROIDS: Strongyloides serology + drug review + EGPA screen Empiric ivermectin if high-risk + ANCA + UA + cardiac workup BAL eosinophil % AEP ≥25%, CEP ≥40% typically AEP (acute, hypoxemic) MePred 60-125 mg IV q6h → pred 40-60 mg PO taper Dramatic response <72h CEP (subacute, peripheral) Pred 0.5-1 mg/kg/d Taper 6-12 months Relapse 50-80% if too fast EGPA features (asthma + ANCA + organ) → mepolizumab 300 mg SC q4wk Add to steroids; reduces relapse meaningfully Observed: ~1 in 12 has + Strongyloides serology; ~1 in 4 is drug-induced; ~1 in 6 reveals EGPA on workup. — gomdori, MD

6. Surveillance, Relapse Management, and FAQ

Long-Term Surveillance

Time PointAssessment
Baseline (before steroid)HRCT, PFTs (FEV1, FVC, DLCO), CBC with diff, total IgE, ANCA, baseline DEXA if expected long course, A1c, LFTs
2 weeksClinical assessment, CXR (should show marked improvement), CBC for eosinophil response
1 monthHRCT (resolution of infiltrates), PFTs (recovery of DLCO)
3, 6, 12 monthsPFTs, CXR, monitor for relapse during taper; A1c if on chronic steroids
Relapse triggersRecurrent cough, dyspnea, peripheral eosinophilia >500/μL, new infiltrates → resume induction prednisone dose
Long-term (CEP)DEXA every 1-2 years on chronic steroids; cataract eye exam annually; monitor for adrenal insufficiency on prolonged taper

Relapse Management for CEP

  1. Confirm relapse with imaging (recurrent infiltrates) and/or BAL eosinophilia
  2. Exclude alternative diagnosis (especially infection during immunosuppression)
  3. Resume induction-dose prednisone 0.5 mg/kg/day until response
  4. Slower taper than initial course (every 4 weeks instead of 2)
  5. If 2 or more relapses: initiate steroid-sparing (mepolizumab or high-dose ICS)
  6. Consider chronic maintenance prednisone 5-10 mg if frequent relapses

Frequently Asked Questions

How is acute eosinophilic pneumonia (AEP) distinguished from chronic eosinophilic pneumonia (CEP)?
AEP is a febrile illness developing over days to weeks with rapidly progressive hypoxemic respiratory failure (often requiring ICU admission), bilateral diffuse infiltrates on CT, and BAL eosinophilia greater than 25 percent. Peripheral blood eosinophilia is often absent at presentation. Smoking initiation or cigarette resumption within 1 month is a key trigger. CEP develops insidiously over weeks to months with fever, weight loss, night sweats, asthma history (50 percent), peripheral eosinophilia greater than 1000 cells/uL, and characteristic peripheral non-segmental upper lobe infiltrates (the photographic negative of pulmonary edema). Both respond dramatically to corticosteroids, but AEP rarely relapses while CEP relapses in 50-80 percent on taper.
What is the standard corticosteroid regimen for eosinophilic pneumonia?
For AEP with respiratory failure: methylprednisolone 60-125 mg IV q6h until extubation/PaO2/FiO2 greater than 300, then transition to prednisone 40-60 mg PO daily for 2-4 weeks, taper over 4 weeks total. For CEP: prednisone 0.5 mg/kg/day (typically 40-60 mg PO daily) for 2 weeks until clinical/radiographic response, then taper by 5-10 mg every 2 weeks targeting 6-12 months total duration. Relapse occurs in 50-80 percent of CEP patients during taper; long-term low-dose prednisone (10-15 mg) or inhaled corticosteroids may be required for years. Steroid-sparing options include mepolizumab 100 mg SC q4 weeks for severe relapsing disease.
What conditions must be excluded before diagnosing idiopathic eosinophilic pneumonia?
Five categories must be systematically excluded: (1) Parasitic infections – Strongyloides, Ascaris, hookworm, Toxocara – send stool ova/parasites and serology, treat with ivermectin/albendazole if Loffler syndrome from helminths suspected. (2) Drug-induced – daptomycin, NSAIDs, nitrofurantoin, sulfonamides, minocycline, phenytoin (over 100 medications implicated) – careful drug history within 6 weeks. (3) ABPA in asthmatics – total IgE greater than 1000 IU/mL, Aspergillus-specific IgE/precipitins. (4) EGPA (Churg-Strauss) – asthma, eosinophilia, vasculitis, mononeuritis multiplex, ANCA in 40 percent. (5) Hypereosinophilic syndrome – eosinophilia greater than 1500 for greater than 6 months with end-organ damage.
What role does bronchoalveolar lavage (BAL) play in diagnosis?
BAL is the diagnostic gold standard, performed via flexible bronchoscopy. BAL eosinophilia greater than 25 percent (often 30-60 percent) confirms eosinophilic lung disease. AEP characteristically shows greater than 25 percent BAL eosinophils despite normal peripheral counts. Concurrent BAL studies should include cell differential, AFB stain and culture, fungal stain and culture, viral PCR panel, cytology for malignancy, and Pneumocystis. Lung biopsy (transbronchial or surgical) is rarely needed when BAL eosinophilia plus characteristic clinical/radiographic features are present, but is required to diagnose EGPA (vasculitis) or to exclude alternative diseases.
What is the prognosis of eosinophilic pneumonia?
Both AEP and CEP have excellent prognosis with appropriate corticosteroid therapy. AEP patients typically achieve dramatic clinical and radiographic improvement within 12-48 hours of corticosteroid initiation; ICU mortality is less than 5 percent with timely diagnosis. AEP rarely relapses (less than 5 percent recurrence). CEP responds within 48-72 hours but recurs in 50-80 percent during corticosteroid taper, requiring long-term low-dose maintenance. Approximately 25 percent develop chronic asthma. Long-term mortality is comparable to age-matched controls. Pulmonary fibrosis is rare (less than 5 percent) and is associated with delayed diagnosis.
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *